Fund moves
9.9%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BNGO · NASDAQ · Laboratory Analytical Instruments
Bionano Genomics (BNGO) · oqro.io/stocks/BNGO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.00−0.04 (−3.85%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Bionano Genomics was filed in the last 90 days. The latest on record was on Jun 13, 2023.
Since 2018, Bionano Genomics insiders reported 12 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 4 different years, most recently 2023.
No open-market sale by an insider of Bionano Genomics (BNGO) was filed with the SEC in the last 90 days.
No trade in Bionano Genomics (BNGO) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−32.0% (−$0.47) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.47 on Nov 13, 2025 to $1.00 on Nov 13, 2026 (−32.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Laboratory Analytical Instruments company based in San Diego, Ca.
Last 12 months
−32.0%
Market value
$11.8M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.39M shares sold short (11.8% of shares outstanding), +2.0% vs the previous count, 7.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$8.17M
+21.4% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $3.73M, at Jun 30, 2026
Backlog
$1.3M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue, fiscal 2025
$28.5M
−7.4% vs the year before
Net income, fiscal 2025
−$26.4M
A loss for the year
Shares outstanding
11.8M
As of Aug 6, 2026
New federal contracts from the last 12 months add up to 0.06% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Federal contracts
26-000852 standard 1-YEAR service contract for saphyr instrument system G350 pop 03/26/2026 to 03/25/2027
The Department of Health and Human Services has committed $18K to Bionano Genomics so far. It runs until Mar 25, 2027.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Insiders of Bionano Genomics reported 12 open-market purchases and 1 sale since 2018; purchases in 4 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $93K3×3 trades | — |
| 2022 | $16K1×1 trade | $72K1×1 trade |
| 2021 | $20K3×3 trades | — |
| 2018 | $193K5×5 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“Departure of President and Chief Executive Officer On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Against the S&P 500 over the year
Since Nov 12, 2025, BNGO is down 37.5% and the index fund is up 10.4%: 48 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BNGO moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.